Published in Arch Gen Psychiatry on January 01, 1989
Chronic paranoid psychosis after misuse of MDMA ("ecstasy") BMJ (1991) 1.65
Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. J Neural Transm (Vienna) (1997) 0.82
Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. Br J Pharmacol (2013) 0.79
Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry (1990) 0.75
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
A molecular and cellular theory of depression. Arch Gen Psychiatry (1997) 6.10
Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet (1998) 5.85
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A (1999) 3.82
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry (1990) 3.57
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA (1997) 3.35
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 2.92
Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry (1993) 2.89
Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1999) 2.78
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci (1998) 2.40
Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol (1993) 2.25
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry (1991) 2.17
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry (1996) 2.04
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry (1994) 2.04
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology (1998) 2.00
Lithium in the treatment of mood disorders. N Engl J Med (1994) 1.97
Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse (1996) 1.97
Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry (1993) 1.88
Activation of human prefrontal cortex during spatial and nonspatial working memory tasks measured by functional MRI. Cereb Cortex (1996) 1.82
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse (1996) 1.75
Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res (1982) 1.70
Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res (1980) 1.70
Toward a neurobiology of delusions. Prog Neurobiol (2010) 1.70
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry (1989) 1.66
Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res (1980) 1.64
Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology (1994) 1.60
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry (1990) 1.56
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry (1993) 1.56
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry (1994) 1.56
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol (1986) 1.56
Caveat emptor: editors beware. Neuropsychopharmacology (2001) 1.51
Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology (1998) 1.51
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry (2006) 1.49
Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. Arch Gen Psychiatry (1989) 1.49
Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res (1989) 1.48
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry (1989) 1.47
A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol (1991) 1.45
Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry (2001) 1.43
Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects. Am J Psychiatry (1991) 1.43
Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry (1996) 1.41
Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry (2012) 1.41
Rapid detoxification from opioid dependence. Am J Psychiatry (1989) 1.40
Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs. Intensive Care Med (1996) 1.38
Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci (1990) 1.34
Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci (1983) 1.32
Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci (1999) 1.32
Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry (2013) 1.31
Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry (1997) 1.31
Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. Am J Psychiatry (1973) 1.30
Quantitative morphology of the caudate and putamen in patients with cocaine dependence. Am J Psychiatry (2001) 1.30
NMDA receptor regulation of memory and behavior in humans. Hippocampus (2001) 1.30
Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry (1984) 1.28
Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated "voices". Biol Psychiatry (1999) 1.25
Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry (1999) 1.25
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction (1994) 1.22
Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry (1994) 1.22
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch Gen Psychiatry (1982) 1.20
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry (1999) 1.20
Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry (1981) 1.17
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) (1999) 1.17
Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry (1999) 1.17
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry (1990) 1.17
Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet (2000) 1.16
Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry (1994) 1.16
The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry (1998) 1.14
Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol (2000) 1.13
Functional neuroanatomical correlates of the effects of stress on memory. J Trauma Stress (1995) 1.12
Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) (1999) 1.12
Dissociation of mnemonic and perceptual processes during spatial and nonspatial working memory using fMRI. Hum Brain Mapp (1998) 1.11
Complications of alcohol withdrawal: pathophysiological insights. Alcohol Health Res World (1998) 1.11
Multiple mechanisms of withdrawal from opioid drugs. Annu Rev Neurosci (1984) 1.10
Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res (1984) 1.10
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) (1998) 1.09
The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry (1986) 1.09
Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin Clin Neuropsychiatry (1999) 1.08
Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry (1996) 1.08
Electrocardiographic T-wave changes during lithium carbonate treatment. JAMA (1971) 1.08
Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry (1997) 1.08
Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry (1985) 1.07
Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry (1996) 1.06
Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry (1997) 1.05
Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry (1999) 1.05
(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology (2000) 1.04